#ESCCongress – Study: Effects of Anacetrapib in Patients with Atherosclerotic Vascular Disease

Effects of Anacetrapib in Patients with Atherosclerotic Vascular Disease – New England Journal of Medicine (free)

Commentaries: Anacetrapib REVEALs ‘Modest’ Effect on Cardiovascular Outcomes – Medscape (free registration required) AND Anacetrapib Finds (Modest) Success Where All Other CETP Inhibitors Failed – TCTMD (free) AND REVEAL Revealed: A Slightly Positive CETP Inhibitor Trial – Cardiobrief (free)

Interesting new drug, but with modest benefits. During the median follow-up period of 4.1 years, the primary outcome occurred in fewer patients in the anacetrapib group than in the placebo group (10.8% vs. 11.8% / absolute risk difference = 1%, meaning 100 patients would have to be treated for 4.1 years to benefit 1 patient)